Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GALE 302

Drug Profile

GALE 302

Alternative Names: Attenuated E39 peptide vaccine - Sellas Life Sciences Group; E39 prime vaccine - Sellas Life Sciences Group; E39'; E39'-GM-CSF-vaccine - Sellas Life Sciences Group; EIWTFSTKV; FBP-J65; Folate binding protein J65 - Sellas Life Sciences Group; GALE-302; J65

Latest Information Update: 08 Jun 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator San Antonio Military Medical Centre; University of Texas M. D. Anderson Cancer Center
  • Developer Sellas Life Sciences Group
  • Class Cancer vaccines; Peptide vaccines; Peptides; Stem cell therapies
  • Mechanism of Action T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Breast cancer; Ovarian cancer

Most Recent Events

  • 31 Mar 2021 Sellas Life Sciences terminates its license for folate binding protein-E39 targeted cancer vaccine in February 2021
  • 01 Dec 2019 Discontinued - Phase-I/II for Breast cancer (Combination therapy, Prevention of relapse, Adjuvant therapy) in USA (Intradermal) (3464169; 9287650)
  • 01 Dec 2019 Discontinued - Phase-I/II for Ovarian cancer (Combination therapy, Prevention of relapse, Adjuvant therapy) in USA (Intradermal) (3464169; 9287650)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top